Trials / Completed
CompletedNCT01624649
A Study to Examine the Progression of Attention-Deficit Hyperactivity Disorder (ADHD) Drug Treatment and to Analyze Associated Factors
Prospective Follow-Up Observational Study to Examine the Progression of ADHD Drug Treatment and to Analyze Associated Factors
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 289 (actual)
- Sponsor
- Janssen Korea, Ltd., Korea · Industry
- Sex
- All
- Age
- 6 Years – 15 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this observational study is to explore the efficacy of methylphenidate hydrochloride in children and adolescents diagnosed with attention-deficit hyperactivity disorder (ADHD) by Kiddie-scheduled for affective disorders (SADS)-present and life time version (K-SADS-PL).
Detailed description
This is a 1-year open-label (all people involved know the identity of the assigned drug), multicenter, single arm, prospective, observational study to explore under natural setting the efficacy of drug treatment in children and adolescents diagnosed with ADHD by K-SADS-PL (K-SADS-PL is a tool used for ADHD diagnosis. Patient may be diagnosed with ADHD by using K-SADS-PL to check if he or she meets the criteria according to Diagnostic and Statistical Manual of Mental Disorders \& edition (DSM-IV). After obtaining informed consent, investigator will prescribe stimulant or non-stimulant ADHD treatment medications (ie, Immediate release \[IR\]/extended release \[ER\]/osmotic release oral system (OROS) methylphenidate, atomoxetine). Efficacy and safety assessments will be performed at 4, 12, 24, 36, and 52 weeks after the first day of giving study drug. Progression of symptom improvement and adherence will be investigated and associated variables (ie, demographic, clinical, familial and treatment factors) will be analyzed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Methylphenidate hydrochloride | Form = tablet, route = oral, administered as a flexible dosage |
| DRUG | Atomoxetine | Form = tablet, route = oral; |
Timeline
- Start date
- 2012-02-01
- Primary completion
- 2014-04-01
- Completion
- 2014-04-01
- First posted
- 2012-06-21
- Last updated
- 2015-06-09
Locations
9 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01624649. Inclusion in this directory is not an endorsement.